2 days ago
Merck & Co. (MRK) Stock: Rises as EU Backs Expanded RSV Drug Approval
TLDR Merck stock climbs 0.65% to $147.90 after positive EU opinion on ENFLONSIA. EU advisers back ENFLONSIA use for high-risk children through a second RSV season. European Commission decision on Merck’s expanded RSV treatment is due in two months. Phase 3 SMART trial data support Merck’s bid to expand RSV prevention in Europe. FDA sets [...]
The post Merck & Co. (MRK) Stock: Rises as EU Backs Expanded RSV Drug Approval appeared first on Blockonomi.
Source: Blockonomi →Related News
- 1 hour ago
Kraken Doubles Spot Market Share Even as Trading Volume Drops 30%
- 2 days ago
SMX (SMX) Stock: Unveils Scientific AI Platform Ahead of 2027 Commercial Launch
- 2 days ago
XPeng Inc. (XPEV) Stock: Unveils Five New EV Models Amid Major UK Expansion
- 2 days ago
Vertiv Holdings Co (VRT) Stock: Introduces New Power Technology for AI and HPC I...
- 2 days ago
Applied Materials (AMAT) Stock: Slides 4% Despite Record $10.41B Revenue and $2....
